Neuroprotection: A new treatment modality for glaucoma?

Current Opinion in Ophthalmology

Volumn 11, Issue 2, 2000, Pages 107-111

  Schwartz, Michal ^a   Yoles, Eti ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; GLUTAMIC ACID; NEUROPROTECTIVE AGENT;

CELL DEATH; CELL SURVIVAL; DEGENERATIVE DISEASE; EXTRACELLULAR MATRIX; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NEUROPROTECTION; OPTIC NERVE DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TISSUE REPAIR;

ANIMALS; CELL DEATH; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; NEUROPROTECTIVE AGENTS; OPHTHALMIC SOLUTIONS; OPTIC NERVE; OPTIC NERVE DISEASES; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 0034023044     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200004000-00007     Document Type: Review

References (40)

1. Yoles E, Schwartz M: Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthalmol 1998, 42:367-372.
2. Sugrue MF: The pharmacology of antiglaucoma drugs. Pharmacol Ther 1989, 43:91-138.
3. Brubaker RF: Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol 1996, 121:473-483.
4. Liesegang TJ: Glaucoma: changing concepts and future directions. Mayo Clin Proc 1996, 71:689-694.
5. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA: Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996, 114:299-305.
6. Neufeld AH, Hernandez MR, Gonzalez M: Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol 1997, 115:497-503.
7. Caprioli J, Kitano S, Morgan JE: Hyperthermia and hypoxia increase tolerance of retinal ganglion cells to anoxia and excitotoxicity. Invest Ophthalmol Vis Sci 1996, 37:2376-2381.
8. Di X, Gordon J, Bullock R: Fluid percussion brain injury exacerbates glutamate-induced focal damage in the rat. J Neurotrauma 1999, 16:195-201.
9. Neufeld AH: New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. J Glaucoma 1998, 7:434-438.
10. Quigley HA: Neuronal death in glaucoma. Prog Retinal Eye Res 1999, 18: 39-57. Ganglion cells undergo apoptotic death in human and experimental glaucoma, opening a way to future therapies to prevent such death.
11. Schwartz M, Belkin M, Yoles E, Solomon A: Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. J Glaucoma 1996, 5:427-432.
12. Dreyer EB, Grosskreutz CL: Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG). Clin Neurosci 1997, 4:270-273.
13. Yoles E, Muller S, Schwartz M: NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. J Neurotrauma 1997, 14:665-675.
14. Neufeld AH, Sawada A, Becker B: Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci U S A 1999, 96:9944-9948. Pharmacologic neuroprotection by inhibition of nitric oxide synthase-2 may prove useful for the treatment of patients with glaucoma.
15. McKinnon SJ: Glaucoma, apoptosis, and neuroprotection. Curr Opin Ophthalmol 1997, 8:28-37.
16. Hall ED, Yonkers PA: Mechanisms of neuronal degeneration secondary to central nervous system trauma or ischemia [letter]. J Neurotrauma 1989, 6: 227-228.
17. Faden AI, Salzman S: Pharmacological strategies in CNS trauma. Trends Pharmacol Sci 1992, 13:29-35.
18. Davis M, Barer D: Neuroprotection in acute ischaemic stroke: II: clinical potential. Vasc Med 1999, 4:149-163.
19. Frerichs KU: Neuroprotective strategies in nature: novel clues for the treatment of stroke and trauma. Acta Neurochir Suppl (Wien) 1999, 73:57-61.
20. Doble A: The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther 1999, 81:163-221.
21. Osborne NN, Ugarte M, Chao M, Chidlow G, Bae JH, Wood JP, Nash MS: Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol 1999, 43(suppl 1):S102-128. Supports the hypothesis that ganglion cell death may result from a particular form of ischemia.
22. Weinreb RN, Zangwill LM: Imaging technologies for assessing neuroprotection in glaucomatous optic neuropathy. Eur J Ophthalmol 1999, 9(suppl 1):S40-43. The confocal scanning laser ophthalmoscope and the scanning laser polarimeter are two new imaging devices that may be helpful in the diagnosis and monitoring of glaucoma. They may also improve the ability to monitor progression of glaucomatous optic neuropathy and allow better assessment of neuroprotective agents.
23. Kaufman PL, Gabelt BT, Cynader M: Introductory comments on neuroprotection. Surv Ophthalmol 1999, 43(suppl 1):S89-90.
24. Levin LA: Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Surv Ophthalmol 1999, 43(suppl 1):S98-101.
25. Roth S, Li B, Rosenbaum PS, Gupta H, Goldstein I, Maxwell KM, Gidday JM: Preconditioning provides complete protection against retinal ischemic injury in rats. Invest Ophthalmol Vis Sci 1998, 39:777-785.
26. Schwartz M, Yoles E: Subtoxic levels of glutamate increase resistance to toxic levels in the rat retina. Invest Ophthalmol Vis Sci 1999, 40:s763. Preliminary indication for protective role of glutamate at subtoxic levels.
27. Isenmann S, Bahr M: Expression of c-Jun protein in degenerating retinal ganglion cells after optic nerve lesion in the rat. Exp Neurol 1997, 147:28-36.
28. Vecino E, Ugarte M, Nash MS, Osborne NN: NMDA induces BDNF expression in the albino rat retina in vivo. Neuroreport 1999, 10:1103-1106. Synthesis of brain-derived neurotrophic factor is increased in ganglion cells immediately after an insult by N-methyl-o-aspartate, This may be a natural protective mechanism of rat retinal ganglion cells.
29. Yoles E, Schwartz M: Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol 1998, 153:1-7. Neurons whose axons are damaged only marginally or not at all after an acute insult will eventually degenerate because of the injury-induced hostility of their environment.
30. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M: Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999, 5:49-55. Autoimmune T cells specific for a component of myelin can protect CNS neurons from secondary degeneration.
31. Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR: Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci 1999, 22:295-299. The innate immune system, represented by activated macrophages, can facilitate regeneration in the severed spinal cord. T-cell autoimmunity in the CNS can, under certain circumstances, protect injured neurons from the spread of damage.
32. Popovich PG, Whitacre CC, Stokes BT: Is spinal cord injury an autoimmune disease? Neuroscientist 1998, 4:71-76.
33. Santambrogio L, Benedetti M, Chao MV, Muzaffar R, Kulig K, Gabellini N, Hochwald G: Nerve growth factor production by lymphocytes. J Immunol 1994, 153:4488-4495.
34. Ehrhard PB, Erb P, Graumann U, Otten U: Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones. Proc Natl Acad Sci U S A 1993, 90:10984-10988.
35. Laquis S, Chaudhary P, Sharma SC: The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res 1998, 784:100-104. Describes a rat model of the hypertensive eye in which cauterizing of limbal-derived episcleral veins leads to an increase in IOP.
36. Brooks DE, Garcia GA, Dreyer EB, Zurakowski D, Franco-Bourland RE: Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res 1997, 58:864-867.
37. Yoles E, Schwartz M: Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol 1998, 116:906-910.
38. Yoles E, Belkin M, Schwartz M: HU-211, a nonpsychotropic cannabinoid, produces short-and long-term neuroprotection after optic nerve axotomy. J Neurotrauma 1996, 13:49-57.
39. Yoles E, Wheeler LA, Schwartz M: Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999, 40:65-73. In addition to their known effect of lowering IOP, α-2 agonists exert a neuroprotective effect.
40. Wen R, Cheng T, Li Y, Cao W, Steinberg RH: Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 1996, 16:5986-5992.